Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Young TIL with or without Aldesleukin in Metastatic Ocular Melanoma
NCT01814046Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2013
- Primary completion
- May 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of young tumor-infiltrating lymphocytes in Ocular melanoma (OM), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 3 years. Started Mar 2013; status: terminated.
02
Drugs
young tumor-infiltrating lymphocytes
03
Conditions
Ocular melanoma (OM)
Beyond the preview
Go deeper on NCT01814046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01814046.